Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

165
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
165
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

197
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
197
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

242
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
242
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

290
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
290
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

347
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
347
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

200
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
200

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Case Report: Kidney preservation using immune checkpoint inhibitors in Muir-Torré syndrome-associated upper tract urothelial carcinoma, with literature review.

Frontiers in immunology·2026
Same author

Prediction of OncotypeDX recurrence score using hematoxylin and eosin-stained whole slide images.

NPJ breast cancer·2026
Same author

Selective IgA Deficiency and COVID-19 Outcomes: A Nationwide Retrospective Cohort Study.

Journal of clinical medicine·2026
Same author

Deep learning on histopathological images to predict breast cancer recurrence risk and chemotherapy benefit: a multicentre, model development and validation study.

The Lancet. Oncology·2026
Same author

<i>De novo</i> biosynthesis of cannabinoids and their analogs in <i>Yarrowia lipolytica</i>.

Biodesign research·2025
Same author

Cancer-Associated Fibroblasts in Solid Tumors and Sarcomas: Heterogeneity, Function, and Therapeutic Implications.

Cells·2025

Related Experiment Video

Updated: Jan 11, 2026

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.5K

How should immune checkpoint inhibitor myocarditis be treated?

Sally Badaan1, Adi Abbass1, Svetlana Tov2

  • 1Department of Medicine, Emek Medical Center, Clalit Health Services, Afula, Israel.

Cardio-Oncology (London, England)
|November 18, 2025
PubMed
Summary

Immune checkpoint inhibitor-related myocarditis (ICIrM) is a rare but serious side effect of cancer therapy. Early detection and personalized treatment, often involving corticosteroids and other immunomodulators, are crucial for managing ICIrM and improving patient outcomes.

Keywords:
Adverse effectsCardiac biomarkersCardiac magnetic resonance imagingCardiac troponinImmune checkpoint inhibitorManagementMyasthenia gravis.MyocarditisMyositis

More Related Videos

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
07:50

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

4.9K
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

12.1K

Related Experiment Videos

Last Updated: Jan 11, 2026

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.5K
Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
07:50

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

4.9K
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

12.1K

Area of Science:

  • Cardio-oncology
  • Immunology
  • Oncology

Background:

  • Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but can cause immune-related adverse events.
  • Immune checkpoint inhibitor-related myocarditis (ICIrM) is a severe complication with high mortality.
  • ICIrM presents heterogeneously, necessitating individualized management strategies.

Purpose of the Study:

  • To provide a framework for the individualized management of immune checkpoint inhibitor-related myocarditis (ICIrM) in adults.
  • To integrate current guidelines, literature, and clinical experience for ICIrM diagnosis and treatment.
  • To highlight the diagnostic and therapeutic challenges posed by ICIrM.

Main Methods:

  • Review of current cardio-oncology guidelines and literature on ICIrM.
  • Analysis of diagnostic tools including ECG, echocardiography, cardiac MRI, and endomyocardial biopsy.
  • Discussion of therapeutic approaches, including corticosteroids and adjunctive immunomodulators like abatacept.
  • Case-based illustration of ICIrM management.

Main Results:

  • ICIrM diagnosis relies on a combination of clinical presentation, cardiac biomarkers (troponin T/I), and advanced imaging (echocardiography with strain, cardiac MRI).
  • Endomyocardial biopsy provides definitive diagnosis and prognostic information.
  • High-dose corticosteroids are the primary therapy, reducing adverse cardiovascular events.
  • Steroid-refractory cases may benefit from immunomodulators, with abatacept under investigation.

Conclusions:

  • ICIrM is a complex condition requiring a personalized diagnostic and therapeutic approach.
  • Early detection through serial monitoring and advanced imaging is key.
  • Corticosteroids form the basis of treatment, with adjunctive therapies for refractory cases.
  • Further research and prospective trials are essential to optimize ICIrM management and patient outcomes.